1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6FC7988F73B8A49E1852581B8003B61D1
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/forging-top-tier-biopharma-digital-strategy-launch-digitization-performance-measurement-mobile-engagement-benchmarks?opendocument
18
19opendocument
2035.173.48.224
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Digital Marketing

Forging Top-Tier Biopharma Digital Strategy: Benchmarks on Launch Digitization, Performance Measurement & Mobile Engagement

ID: 5482


Features:

8 Info Graphics

24 Data Graphics

500+ Metrics


Pages/Slides: 41


Published: 2017


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Forging Top-Tier Biopharma Digital Strategy: Benchmarks on Launch Digitization, Performance Measurement & Mobile Engagement”

STUDY OVERVIEW


Digital Marketing has transformed the speed with which patients, physicians, payers and other customer groups can be engaged during a new product launch. This instant access can rapidly enhance a launch trajectory and enable pharmaceutical and medical device companies to effectively maintain these relationships over product and treatment lifecycles.

As a result, organizations are investing more than ever in digital marketing to learn about their customers, build better relationships, leverage effective online media and maximize revenue. However, with greater investment, digital marketers also face the onus of delivering maximum results with available resources.

Best Practices, LLC conducted this research to establish new benchmarks and provide critical insights into how leading pharmaceutical and medical device firms use new tools and tactics to create digital programs with impact. In particular, this study delivers benchmarks around key performance areas including digital strategy, launch excellence, performance & ROI measurement, analytics, mobile engagement, social media, electronic health records, and digital health & innovation.

KEY TOPICS

  • Digitizing NPP, Launch & High-growth Products
  • Performance Measurement
  • Mobile Engagement & Digital Health
  • Innovative Channels, Programs & Activities

KEY METRICS

  • What is the impact of digital support on the listed clinical and medical focused pre-launch product development programs?
  • Rank the top 2 most effective metric TYPES for measuring digital performance in each of the following channels
  • What level of ROI have you been able to measure for the following digital activities in your company?
  • How valuable are each of the listed information streams and sources in providing data that Digital Marketing teams can use to distill insights and improve customer engagement?
  • How has your Digital Marketing group made use of social media over the past year?

SAMPLE KEY FINDINGS

  • Email marketing, websites, and digital content & collateral building show the highest ROI among surveyed digital activities.
  • A majority of digital marketing teams are using social media strictly for social listening and data collection – rather than direct customer interactions.

METHODOLOGY


Best Practices, LLC engaged 21 digital, multichannel marketing and other commercial leaders from 19 leading healthcare organizations through a benchmarking survey. Close to two-thirds of the participants serve at director level or above.


Industries Profiled:
Diagnostic; Biopharmaceutical; Pharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Clinical Research; Health Care; Consulting; Laboratories


Companies Profiled:
Alere; Alnylam Pharmaceuticals; AstraZeneca; Bayer; Boehringer Ingelheim; CMIC; Daiichi Sankyo; EMD Serono; Medtronic; Merck; MSD; Novartis; Precision For Value; Roche; Salix Pharmaceutical; Sanofi; Takeda Pharmaceuticals; The Himalaya Drug Company; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.